
Third Rock's Ambys hauls $140M for liver disease, inking Takeda deal ahead of launch
It won’t shock anyone that a new company has rolled off Third Rock’s startup conveyor belt (this VC firm is a machine at creating new companies), but their latest venture is leaping off the start line with a distinct advantage: $140 million in launch money and a rare deal with Big Pharma partner Takeda.
The new company is called Ambys Medicines, christened after the Mexican salamander famed for regenerating limbs: Ambystoma mexicanum. You guessed it, the company will be working in regenerative medicine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.